



Claims

1. A compound of the formula [I]:



- 5 wherein G^1 is an alkyl which is substituted by a halogen atom or an alkoxy, or a group of the formula:



- 10 wherein ring B is benzene ring, naphthalene ring, a monocyclic or bicyclic aromatic heterocycle or a cycloalkane, and the benzene ring, the naphthalene ring, the monocyclic or bicyclic aromatic heterocycle and the cycloalkane may be substituted by 1 to 3 substituent(s), which is(are) the same or different, and selected from the group consisting of a halogen atom, nitro, an optionally substituted alkyl, an optionally substituted alkoxy, an optionally substituted amino, an optionally substituted carbamoyl, hydroxy and cyano,
- 15 W is a single bond, or a $C_1 - C_4$ alkylene which may be substituted by 1 or 2 alkyl(s),
- 20 Q^1 and Q^2 may be the same or different, and each is hydrogen atom, a halogen atom or an alkyl,
- 25 n is 0, 1, 2, 3 or 4,
- R^1 is hydrogen atom, an optionally substituted alkyl, an optionally substituted cycloalkyl, an optionally substituted phenyl or an optionally substituted heterocyclic group,


Z^1 , Z^2 , Z^3 and Z^4 may be the same or different, and each is CH or N, provided that 3 or more of Z^1 , Z^2 , Z^3 and Z^4 should not be N at the same time,

G^2 is hydrogen atom, $-NR^3R^4$, $-OR^5$, $-SR^5$, $-COR^6$, $-CHR^7R^8$, or a heterocyclic group,

where R^3 to R^8 each independently is hydrogen atom, an optionally substituted alkyl, an alkenyl, an alkynyl, hydroxy, an alkoxy, an optionally substituted amino, an optionally substituted alkanoyl, an optionally substituted carbamoyl, an alkoxyoxalyl, an alkylsulfonyl, an optionally substituted cycloalkyl, an optionally substituted phenyl, an optionally substituted heterocyclic group, a carbonyl substituted by an optionally substituted cycloalkyl, a carbonyl substituted by an optionally substituted phenyl or a carbonyl substituted by an optionally substituted heterocyclic group,

or a pharmaceutically acceptable salt thereof.

2. A compound of the formula [Ia]:



wherein ring A is benzene ring or a monocyclic aromatic heterocycle, and the benzene ring and the monocyclic aromatic heterocycle may be substituted by 1 to 3 substituent(s), which is(are) the same or different, and selected from the group consisting of a halogen atom, nitro, an optionally substituted alkyl, an optionally substituted alkoxy, an optionally substituted amino, an

optionally substituted carbamoyl, hydroxy and cyano,
Q¹ is hydrogen atom, a halogen atom or an alkyl,
W is a single bond, or a C₁ - C₄ alkylene which may be
substituted by 1 or 2 alkyl(s),
5 n is 0, 1, 2, 3 or 4,
R¹ is hydrogen atom, an optionally substituted alkyl, an
optionally substituted cycloalkyl, an optionally
substituted phenyl or an optionally substituted
heterocyclic group,
10 Z is CH or N,
R² is hydrogen atom, -NR³R⁴, -OR⁵, -COR⁶ or -CHR⁷R⁸,
where R³ to R⁸, each independently is hydrogen atom,
an optionally substituted alkyl, an alkenyl, an
alkynyl, hydroxy, an alkoxy, an optionally
15 substituted amino, an optionally substituted
alkanoyl, an optionally substituted carbamoyl, an
alkoxyoxalyl, an alkylsulfonyl, an optionally
substituted cycloalkyl, an optionally substituted
phenyl, an optionally substituted heterocyclic
20 group, a carbonyl substituted by an optionally
substituted cycloalkyl, a carbonyl substituted by an
optionally substituted phenyl or a carbonyl
substituted by an optionally substituted
heterocyclic group,
25 or a pharmaceutically acceptable salt thereof.

3. The compound according to Claim 2, wherein Q¹ is hydrogen atom, or a pharmaceutically acceptable salt thereof.

30 4. The compound according to Claim 2, wherein the ring A is a benzene ring which may be substituted by 1 to 3 substituent(s), which is(are) the same or different, and selected from the group consisting of a halogen atom, nitro, an optionally substituted alkyl, an optionally substituted alkoxy, an optionally
35 substituted amino and cyano, and W is a single bond, or a pharmaceutically acceptable salt thereof.

5. The compound according to Claim 2, wherein n is 0 or 1, or a pharmaceutically acceptable salt thereof
- 5 6. The compound according to Claim 2, wherein (1) n is 0 and R¹ is an optionally substituted alkyl, (2) n is 1 and R¹ is an optionally substituted cycloalkyl, (3) n is 1 and R¹ is an optionally substituted phenyl, (4) n is 1 and R¹ is an optionally substituted heterocyclic group, (5) n is 0 and R¹ is an
10 optionally substituted cycloalkyl, and (6) n is 0 and R¹ is an optionally substituted heterocyclic group, or a pharmaceutically acceptable salt thereof.
- 15 7. The compound according to Claim 2, wherein R² is -NR³R⁴ or -OR⁵, or a pharmaceutically acceptable salt thereof.
- 20 8. The compound according to Claim 2, wherein R² is -NHR⁴, and R⁴ is an optionally substituted alkyl, an alkenyl, an optionally substituted alkanoyl, an optionally substituted carbamoyl, an optionally substituted cycloalkyl, an optionally substituted phenyl, an optionally substituted heterocyclic group, a carbonyl substituted by an optionally substituted cycloalkyl or a carbonyl substituted by an optionally substituted heterocyclic group, or a pharmaceutically acceptable salt
25 thereof.
- 30 9. The compound according to Claim 3, wherein the ring A is a benzene ring which may be substituted by 1 or 2 substituent(s), which is(are) the same or different, and selected from the group consisting of a halogen atom, an optionally substituted alkyl, an optionally substituted alkoxy, an optionally substituted amino and cyano,
W is a single bond,
n is 0 or 1,
35 R¹ is hydrogen atom, an optionally substituted alkyl, an optionally substituted cycloalkyl, an optionally substituted

phenyl or an optionally substituted heterocyclic group,
Z is CH or N,

R² is hydrogen atom, -NR³R⁴, -OR⁵, -COR⁶ or -CHR⁷R⁸,

Where R³ to R⁸ each independently is hydrogen atom, an
5 optionally substituted alkyl, an alkenyl, an alkoxy, an
optionally substituted alkanoyl, an optionally substituted
carbamoyl, an alkoxyoxalyl, an optionally substituted
cycloalkyl, an optionally substituted phenyl, an
optionally substituted heterocyclic group, a carbonyl
10 substituted by an optionally substituted cycloalkyl or a
carbonyl substituted by an optionally substituted
heterocyclic group,

or a pharmaceutically acceptable salt thereof.

15 10. The compound according to Claim 3, wherein the ring A is
a benzene ring which may be substituted by 1 or 2 substituent(s),
which is(are) the same or different, and selected from the group
consisting of a halogen atom, an alkyl optionally substituted
by halogen(s), an alkoxy, an amino optionally substituted by
20 alkyl(s) and cyano,

W is a single bond,

n is 0 or 1,

R¹ is (1) hydrogen atom,

(2) an alkyl optionally substituted by group(s) selected
25 from the group consisting of phenyl, an alkoxy, an
alkylamino, a dialkylamino, an alkanoylamino, an
alkylsulfonylamino, a carbamoyl optionally
substituted by alkyl(s), hydroxy, carboxy and cyano,

(3) a cycloalkyl optionally substituted by group(s)
30 selected from the group consisting of the following
(i) to (v):

(i) hydroxy,

(ii) an alkoxy optionally substituted by alkoxy(s),

(iii) an amino optionally substituted by group(s)

35 selected from the group consisting of an alkyl, an
alkanoyl and an alkylsulfonyl,

(iv) a carbamoyl optionally substituted by alkyl(s), and
 (v) an alkyl optionally substituted by group(s) selected
 from the group consisting of hydroxy, an alkoxy and
 amino,

5 (4) a phenyl optionally substituted by group(s) selected
 from the group consisting of the following (i) to (vi):

(i) a halogen atom,

(ii) an alkyl optionally substituted by group(s)
 selected from the group consisting of a halogen atom,
 10 hydroxy and phenylsulfonyl,

(iii) cyano,

(iv) an alkoxy,

(v) an amino optionally substituted by group(s) selected
 from the group consisting of an alkyl and an
 15 alkylsulfonyl,

(vi) a carbonyl substituted by a heterocyclic group, or

(5) a heterocyclic group optionally substituted by
 group(s) selected from the group consisting of the
 following (i) to (iv):

20 (i) an alkoxy carbonyl,

(ii) an alkyl optionally substituted by group(s)
 selected from the group consisting of hydroxy, an
 alkoxy and a carbamoyl optionally substituted by
 alkyl(s),

25 (iii) an alkanoyl and

(iv) an alkylsulfonyl,

Z is CH or N,

R^2 is hydrogen atom, $-NR^3R^4$, $-OR^5$, $-COR^6$ or $-CHR^7R^8$,

where R^3 to R^8 each independently is:

30 (1) hydrogen atom,

(2) an alkyl optionally substituted by group(s) selected
 from the group consisting of the following (i) to (vii):

(i) hydroxy,

(ii) an alkoxy,

35 (iii) an amino optionally substituted by group(s)
 selected from the group consisting of an alkyl, an

alkanoyl and an alkylsulfonyl,
(iv) an alkoxycarbonyl,
(v) a cycloalkyl optionally substituted by group(s)
selected from the group consisting of the following
5 a) to g):

- a) hydroxy,
- b) an amino optionally substituted by alkyl(s),
- c) an alkanoylamino,
- d) an alkylsulfonylamino,
- 10 e) an alkyl optionally substituted by group(s)
selected from the group consisting of hydroxy, an
alkoxy, amino, a carbamoyl optionally substituted
by alkyl(s),
- f) carboxy and

15 g) a carbamoyl optionally substituted by alkyl(s),
(vi) a phenyl optionally substituted by group(s)
selected from the group consisting of a halogen atom,
an alkoxy and morpholinylcarbonyl, and
(vii) a heterocyclic group optionally substituted by
20 alkyl(s),

(3) an alkenyl,
(4) an alkoxy,
(5) an alkanoyl optionally substituted by group(s)
selected from the group consisting of the following (i)
25 to (iv):

- (i) hydroxy,
- (ii) an alkoxy,
- (iii) an amino optionally substituted by group(s)
selected from the group consisting of an alkyl and an
30 alkanoyl,

(iv) an alkoxycarbonyl,
(6) a carbamoyl optionally substituted by alkyl(s),
(7) an alkoxyoxalyl,
(8) a cycloalkyl optionally substituted by group(s)
35 selected from the group consisting of the following (i)
to (vii):

- (i) a halogen atom,
(ii) hydroxy,
(iii) an alkoxy,
(iv) an amino optionally substituted by group(s)
5 selected from the group consisting of an alkyl, an
alkanoyl, an alkoxycarbonyl and an alkylsulfonyl,
(v) an alkyl optionally substituted by group(s) selected
from the group consisting of hydroxy, an alkoxy, amino,
a carbamoyl optionally substituted by alkyl(s),
10 (vi) an alkanoyloxy and
(vii) a carbamoyl optionally substituted by alkyl(s),
(9) a phenyl optionally substituted by group(s) selected
from the group consisting of a halogen atom and an alkoxy,
(10) a heterocyclic group optionally substituted by
15 group(s) selected from the group consisting of the
following (i) to (vii):
(i) an alkyl optionally substituted by group(s)
selected from the group consisting of phenyl,
hydroxy, an alkoxy, amino and a carbamoyl optionally
20 substituted by alkyl(s),
(ii) an alkoxycarbonyl,
(iii) an alkanoyl,
(iv) an alkylsulfonyl,
(v) oxo,
25 (vi) a carbamoyl optionally substituted by alkyl(s),
(vii) an aminosulfonyl optionally substituted by
alkyl(s),
(11) a carbonyl substituted by a cycloalkyl optionally
substituted by group(s) selected from the group consisting
30 of hydroxy, amino and an alkanoylamino, or
(12) a heterocyclic group-substituted carbonyl,
or a pharmaceutically acceptable salt thereof.

11. The compound according to Claim 3, wherein the ring A is
35 a benzene ring which may be substituted by 1 or 2 substituent(s),
which is(are) the same or different, and selected from the group

consisting of fluorine atom, chlorine atom, an alkyl optionally substituted by halogen(s) and an alkoxy,

W is a single bond,

n is 0 or 1,

5 R¹ is (1) hydrogen atom,

(2) an alkyl optionally substituted by group(s) selected from the group consisting of phenyl, an alkoxy, an alkylamino, a dialkylamino, an alkanoylamino, an alkylsulfonylamino, a carbamoyl optionally substituted
10 by alkyl(s), hydroxy, carboxy, cyano, and cycloalkyl,
(3) a cycloalkyl optionally substituted by group(s) selected from the group consisting of the following (i) to (v):

(i) hydroxy,

15 (ii) an alkoxy optionally substituted by alkoxy(s),

(iii) an amino optionally substituted by group(s) selected from the group consisting of an alkyl, an alkanoyl and an alkylsulfonyl,

(iv) a carbamoyl optionally substituted by alkyl(s),

20 (v) an alkyl optionally substituted by group(s) selected from the group consisting of hydroxy and amino,

(4) a phenyl optionally substituted by group(s) selected from the group consisting of the following (i) to (iv):

25 (i) a halogen atom,

(ii) an alkyl optionally substituted by halogen atom(s),

(iii) cyano, and

(iv) an alkoxy, or

(5) a heterocyclic group optionally substituted by
30 alkylsulfonyl or alkanoyl,

Z is CH or N,

R² is hydrogen atom, -NR³R⁴, -OR⁵, or -COR⁶,

Where R³ to R⁶ each independently is:


(1) hydrogen atom,

35 (2) an alkyl optionally substituted by group(s) selected from the group consisting of the following (i) to (vii):

- (i) hydroxy,
(ii) an alkoxy,
(iii) an alkoxycarbonyl,
(iv) a cycloalkyl optionally substituted by group(s)
5 selected from the group consisting of the following
a) to e):
a) hydroxy,
b) an amino optionally substituted by alkyl(s),
c) an alkanoylamino,
10 d) an alkyl optionally substituted by group(s)
selected from the group consisting of hydroxy, amino
and a carbamoyl optionally substituted by alkyl(s),
and
e) a carbamoyl optionally substituted by alkyl(s),
15 (v) a phenyl optionally substituted by alkoxy(s),
(vi) a heterocyclic group, and
(vii) an amino optionally substituted by the group(s)
selected from alkanoyl(s) and alkylsulfonyl(s),
(3) an alkenyl,
20 (4) an alkoxy,
(5) an alkanoyl optionally substituted by group(s)
selected from the group consisting of an alkoxy, an amino
optionally substituted by alkanoyl(s), and an
alkoxycarbonyl,
25 (6) a cycloalkyl optionally substituted by group(s)
selected from the group consisting of the following (i)
to (v):
(i) hydroxy,
(ii) an alkoxy,
30 (iii) an amino optionally substituted by group(s)
selected from the group consisting of an alkyl, an
alkanoyl, an alkoxycarbonyl and an alkylsulfonyl,
(iv) an alkyl optionally substituted by group(s)
selected from the group consisting of hydroxy, amino
35 and a carbamoyl optionally substituted by alkyl(s),
(v) a carbamoyl optionally substituted by alkyl(s),

- (7) a heterocyclic group optionally substituted by group(s) selected from the group consisting of the following (i) to (vi):
- (i) an alkyl optionally substituted by phenyl(s),
 - (ii) an alkoxycarbonyl,
 - (iii) an alkylsulfonyl
 - (iv) an alkanoyl,
 - (v) a carbamoyl optionally substituted by alkyl(s), and
 - (vi) an aminosulfonyl optionally substituted by alkyl(s),
- (8) a carbonyl substituted by a cycloalkyl optionally substituted by group(s) selected from the group consisting of hydroxy and amino, or
- (9) a heterocyclic group-substituted carbonyl,
- or a pharmaceutically acceptable salt thereof.

12. A compound of the formula [Ib]:



- wherein R^{11} is a group selected from the group consisting of hydrogen atom, a halogen atom, a $C_1 - C_4$ alkyl optionally substituted by halogen(s) and a $C_1 - C_4$ alkoxy, k is 1 or 2, and when k is 2, two of R^{11} s may be the same or different,
- R^{12} is (1) a $C_1 - C_5$ alkyl optionally substituted by group(s) selected from the group consisting of hydroxy, an alkoxy, cyano, amino, tetrahydropyranyl, tetrahydrofuryl and a carbamoyl optionally substituted by alkyl(s),
- (2) a $C_3 - C_4$ cycloalkylmethyl,
 - (3) a $C_3 - C_4$ cycloalkyl,

- (4) carbamoylmethyl,
- (5) a benzyl optionally substituted by group(s) selected from the group consisting of cyano, a halogen atom, a $C_1 - C_3$ alkoxy, a $C_1 - C_3$ alkyl and a halogen-substituted $C_1 - C_3$ alkyl,
- (6) tetrahydropyranyl,
- (7) tetrahydrofuryl, and
- (8) a piperidyl optionally substituted by group(s) selected from the group consisting of an alkyl, an alkanoyl, an alkylsulfonyl, an alkoxy carbonyl and a carbamoylalkyl optionally substituted by alkyl(s),
- Z^5 is CH or N,
- R^{13} is (1) a $C_1 - C_6$ alkyl optionally substituted by group(s) selected from the group consisting of the following (i) to (xiv):
- (i) a $C_5 - C_7$ cycloalkyl optionally substituted by group(s) selected from the group consisting of the following a) to e):
- a) hydroxy
- b) an amino optionally substituted by $C_1 - C_4$ alkyl(s),
- c) a $C_1 - C_4$ alkanoylamino,
- d) a $C_1 - C_4$ alkyl optionally substituted by group(s) selected from the group consisting of hydroxy, amino, and a carbamoyl optionally substituted by $C_1 - C_4$ alkyl(s), and
- e) a carbamoyl optionally substituted by $C_1 - C_4$ alkyl(s),
- (ii) hydroxy,
- (iii) a carbamoyl optionally substituted by $C_1 - C_4$ alkyl(s),
- (iv) a piperidyl optionally substituted by group(s) selected from the group consisting of an alkyl, an alkanoyl, an alkylsulfonyl and oxo,
- (v) a pyrrolidinyl optionally substituted by group(s) selected from the group consisting of

- an alkyl, an alkanoyl, an alkylsulfonyl and
oxo,
- (vi) a tetrahydropyranyl optionally substituted by
hydroxy(s),
- 5 (vii) an imidazoliny1 optionally substituted by
group(s) selected from the group consisting of
an alkyl and oxo,
- (viii) an imidazolidiny1 optionally substituted by
group(s) selected from the group consisting of
10 an alkyl and oxo,
- (ix) a piperadiny1 optionally substituted by
group(s) selected from the group consisting of
an alkyl and oxo,
- (x) a hexahydropyrimidiny1 optionally substituted
15 by group(s) selected from the group consisting
of an alkyl and oxo,
- (xi) a pyridyl optionally substituted by alkyl(s),
(xii) furyl,
- (xiii) tetrahydroisothiazoly1 optionally
20 substituted by oxo(s), and
- (xiv) an amino optionally substituted by the group(s)
selected from alkanoyl(s) and
alkylsulfonyl(s),
- (2) a $C_5 - C_7$ cycloalkyl optionally substituted by group(s)
25 selected from the group consisting of the following
(i) to (v):
- (i) hydroxy,
- (ii) a $C_1 - C_4$ alkoxy,
- (iii) a $C_1 - C_4$ alkyl optionally substituted by
30 group(s) selected from the group consisting of
hydroxy, amino and a carbamoyl optionally
substituted by $C_1 - C_4$ alkyl(s),
- (iv) a carbamoyl optionally substituted by $C_1 - C_4$
alkyl(s), and
- 35 (v) an amino optionally substituted by group(s)
selected from the group consisting of $C_1 - C_4$

alkyl(s) and $c_1 - c_4$ alkylsulfonyl(s), or
 (3) a heterocyclic group optionally substituted by
 group(s) selected from the group consisting of the
 following (i) to (vii):

- 5 (i) an alkyl optionally substituted by group(s)
 selected from the group consisting of a halogen,
 amino, hydroxy, phenyl and oxo,
- (ii) an aminosulfonyl optionally substituted by
 alkyl(s),
- 10 (iii) an alkylsulfonyl optionally substituted by
 halogen(s),
- (iv) a carbamoyl optionally substituted by alkyl(s),
- (v) hydroxy,
- (vi) an alkoxy carbonyl, and
- 15 (vii) oxo,

or a pharmaceutically acceptable salt thereof.

13. The compound according to Claim 12, wherein R^{12} is

- 20 (1) a $c_1 - c_5$ alkyl optionally substituted by group(s)
 selected from the group consisting of hydroxy, alkoxy,
 tetrahydropyranyl and tetrahydrofuryl,
- (2) a $c_3 - c_4$ cycloalkylmethyl,
- (3) a $c_3 - c_4$ cycloalkyl,
- (4) carbamoylmethyl,
- 25 (5) a benzyl optionally substituted by group(s)
 selected from the group consisting of cyano, a halogen
 atom, a $c_1 - c_3$ alkoxy, a $c_1 - c_3$ alkyl and a
 halogen-substituted $c_1 - c_3$ alkyl,
- (6) tetrahydropyranyl,
- 30 (7) tetrahydrofuryl, or
- (8) a piperidyl optionally substituted by
 alkylsulfonyl or alkanoyl,

R^{13} is (1) a $c_1 - c_6$ alkyl optionally substituted by group(s)
 selected from the group consisting of the following
 35 (i) to (iv):
 (i) a $c_5 - c_7$ cycloalkyl optionally substituted by

group(s) selected from the group consisting of the following a) to e):

- a) hydroxy
 - b) an amino optionally substituted by $c_1 - c_4$ alkyl(s),
 - c) a $c_1 - c_4$ alkanoylamino,
 - d) a $c_1 - c_4$ alkyl optionally substituted by group(s) selected from the group consisting of hydroxy, amino, and a carbamoyl optionally substituted by $c_1 - c_4$ alkyl(s), and
 - e) a carbamoyl optionally substituted by $c_1 - c_4$ alkyl(s),
 - (ii) hydroxy,
 - (iii) a carbamoyl optionally substituted by $c_1 - c_4$ alkyl(s), and
 - (iv) amino optionally substituted by the group(s) selected from alkanoyl(s) and alkylsulfonyl(s),
- (2) a $c_5 - c_7$ cycloalkyl optionally substituted by group(s) selected from the group consisting of the following (i) to (v):
- (i) hydroxy,
 - (ii) a $c_1 - c_4$ alkoxy
 - (iii) a $c_1 - c_4$ alkyl optionally substituted by group(s) selected from the group consisting of hydroxy, amino and a carbamoyl optionally substituted by $c_1 - c_4$ alkyl(s),
 - (iv) a carbamoyl optionally substituted by $c_1 - c_4$ alkyl(s), and
 - (v) an amino optionally substituted by group(s) selected from the group consisting of $c_1 - c_4$ alkyl(s) and $c_1 - c_4$ alkylsulfonyl(s), or
- (3) a heterocyclic group optionally substituted by group(s) selected from the group consisting of the following (i) to (vi):
- (i) alkylsulfonyl(s),

- (ii) alkoxy-carbonyl(s),
- (iii) carbamoyl(s) optionally substituted by alkyl(s),
- (iv) alkanoyl(s),
- 5 (v) aminosulfonyl(s) optionally substituted by alkyl(s), and
- (vi) alkyl(s)

or a pharmaceutically acceptable salt thereof.

- 10 14. The compound according to Claim 13, wherein R^{11} is a group selected from the group consisting of hydrogen atom, fluorine atom, chlorine atom, methyl, trifluoromethyl and methoxy, k is 1 or 2, and when k is 2, two of R^{11} s may be the same or different,
- 15 R^{12} is a $C_1 - C_5$ alkyl optionally substituted by hydroxy, cyclopropylmethyl, cyclobutyl, carbamoylmethyl, tetrahydropyranyl, tetrahydrofuryl, tetrahydropyranylmethyl, tetrahydrofurylmethyl or piperidyl optionally substituted by the group selected from alkylsulfonyl and alkanoyl,
- 20 or a pharmaceutically acceptable salt thereof.

15. The compound according to Claim 13, wherein R^{11} is hydrogen atom, fluorine atom, chlorine atom, trifluoromethyl or methyl, k is 1,
- 25 R^{12} is ethyl, isopropyl, isobutyl, 2-hydroxy-2-methylpropyl, cyclopropylmethyl, cyclobutyl, carbamoylmethyl, 4-tetrahydropyranyl, 3-tetrahydrofuryl, tetrahydropyranylmethyl, tetrahydrofurylmethyl, methoxymethyl, 3-hydroxy-3-methylbutyl or 4-piperidyl
- 30 substituted by methanesulfonyl or acetyl,
- R^{13} is (1) a $C_1 - C_6$ alkyl optionally substituted by group(s) selected from the group consisting of the following (i) and (iii):
- (i) a $C_5 - C_7$ cycloalkyl optionally substituted by
- 35 group(s) selected from the group consisting of hydroxy, a hydroxy $C_1 - C_4$ alkyl, a $C_1 - C_4$ alkyl, amino

and a carbamoyl optionally substituted by $C_1 - C_4$ alkyl(s),

(ii) hydroxy, and

(iii) an amino optionally substituted by group(s) selected from the group consisting of alkyl(s) and alkylsulfonyl(s),

(2) a $C_5 - C_7$ cycloalkyl optionally substituted by group(s) selected from the group consisting of the following (i) to (v):

(i) hydroxy,

(ii) a $C_1 - C_4$ alkoxy

(iii) a $C_1 - C_4$ alkyl optionally substituted by group(s) selected from the group consisting of hydroxy, amino and a carbamoyl optionally substituted by $C_1 - C_4$ alkyl(s),

(iv) a carbamoyl optionally substituted by $C_1 - C_4$ alkyl(s), and

(v) an amino optionally substituted by group(s) selected from the group consisting of alkyl(s) and alkylsulfonyl(s),

(3) piperidinyl optionally substituted by group(s) selected from the group consisting of the following (i) to (vi):

(i) alkylsulfonyl(s),

(ii) alkoxycarbonyl(s),

(iii) carbamoyl(s) optionally substituted by alkyl(s),

(iv) alkanoyl(s),

(v) aminosulfonyl(s) optionally substituted by alkyl(s), and

(vi) alkyl(s)

(4) pyrrolidinyl optionally substituted by alkylsulfonyl,

or a pharmaceutically acceptable salt thereof.

16. A pharmaceutical composition comprising the compound

according to any one of Claims 1 to 15 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

- 5 17. A method for inhibiting p38 MAP kinase, which comprises administering the compound according to any one of Claims 1 to 15 or a pharmaceutically acceptable salt thereof to a human in need thereof.
- 10 18. A method of prophylaxis or treatment for diseases related to the activation of p38 MAP kinase or the excessive production of inflammatory mediators concerned with p38 MAP kinase, which comprises administering the compound according to any one of Claims 1 to 15 or a pharmaceutically acceptable salt thereof
- 15 to a human in need thereof.
19. A method of prophylaxis or treatment for diseases selected from the group consisting of arthritis, inflammatory bowel disease, inflammatory dermal disease, inflammatory
- 20 respiratory disease, inflammatory optical disease, nephritis, hepatitis, systemic inflammatory disease, shock, cerebrovascular disease, ischemic cardiac diseases, osteoporosis, multiple sclerosis, diabetes, malignant tumor, cachexia, Alzheimer's disease, Parkinson's disease, acquired
- 25 immunodeficiency syndrome, arterial sclerosis, disseminated intravascular coagulation syndrome, rejection and graft-versus-host diseases by organ transplantation, which comprises administering the compound according to any one of Claims 1 to 15 or a pharmaceutically acceptable salt thereof
- 30 to a human in need thereof.